723 related articles for article (PubMed ID: 6176669)
41. Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations.
Agah R; Shau H; Mazumder A
Cancer Immunol Immunother; 1987; 24(3):247-52. PubMed ID: 3594487
[TBL] [Abstract][Full Text] [Related]
42. Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2.
Imaya H; Matsuura H; Kudo M; Nakazawa S
Cancer Immunol Immunother; 1988; 27(1):13-6. PubMed ID: 3260819
[TBL] [Abstract][Full Text] [Related]
43. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.
Scheid C; Young R; McDermott R; Fitzsimmons L; Scarffe JH; Stern PL
Cancer Immunol Immunother; 1994 Feb; 38(2):119-26. PubMed ID: 8306367
[TBL] [Abstract][Full Text] [Related]
44. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity.
Tanio Y; Watanabe M; Osaki T; Tachibana I; Kawase I; Kuritani T; Saito S; Masuno T; Kodama N; Furuse K
Jpn J Cancer Res; 1992 Jul; 83(7):736-45. PubMed ID: 1325431
[TBL] [Abstract][Full Text] [Related]
45. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2.
Whiteside TL; Heo DS; Takagi S; Johnson JT; Iwatsuki S; Herberman RB
Cancer Immunol Immunother; 1988; 26(1):1-10. PubMed ID: 3257898
[TBL] [Abstract][Full Text] [Related]
46. Natural cytotoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK432.
Yanagawa E; Uchida A; Micksche M
Cancer Immunol Immunother; 1984; 17(1):1-6. PubMed ID: 6563940
[TBL] [Abstract][Full Text] [Related]
47. Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.
Fossati G; Balsari A; Taramelli D; Sensi ML; Pellegris G; Nava M; Parmiani G
Cancer Immunol Immunother; 1982; 14(2):99-104. PubMed ID: 6965234
[TBL] [Abstract][Full Text] [Related]
48. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.
Nanbara S; Arinaga S; Akiyoshi T
Cancer Immunol Immunother; 1989; 29(4):237-41. PubMed ID: 2568886
[TBL] [Abstract][Full Text] [Related]
49. Effects of phenytoin on cell-mediated immunity.
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Tsuda N; Matsui Y; Mogami H
Cancer Immunol Immunother; 1988; 26(2):176-9. PubMed ID: 3258793
[TBL] [Abstract][Full Text] [Related]
50. Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.
Nicolet CM; Surfus JM; Hank JA; Sondel PM
Cancer Immunol Immunother; 1998 Aug; 46(6):327-37. PubMed ID: 9756417
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells.
Mahvi DM; Carper SW; Storm FK; Teal SR; Sondel PM
Cancer Immunol Immunother; 1993 Aug; 37(3):181-6. PubMed ID: 8334681
[TBL] [Abstract][Full Text] [Related]
52. Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.
Navarrete-Galvan L; Guglielmo M; Cruz Amaya J; Smith-Gagen J; Lombardi VC; Merica R; Hudig D
J Transl Med; 2022 Apr; 20(1):151. PubMed ID: 35366943
[TBL] [Abstract][Full Text] [Related]
53. A protein fraction from aged garlic extract enhances cytotoxicity and proliferation of human lymphocytes mediated by interleukin-2 and concanavalin A.
Morioka N; Sze LL; Morton DL; Irie RF
Cancer Immunol Immunother; 1993 Oct; 37(5):316-22. PubMed ID: 8402735
[TBL] [Abstract][Full Text] [Related]
54. Sensitization of resting T cells to autologous natural-killer-cell-mediated lysis by phytohemagglutinin.
Baraz L; Kotler M; Condiotti R; Nagler A
Cancer Immunol Immunother; 1999 Dec; 48(9):507-16. PubMed ID: 10602888
[TBL] [Abstract][Full Text] [Related]
55. Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.
Ames IH; Gagne GM; Garcia AM; John PA; Scatorchia GM; Tomar RH; McAfee JG
Cancer Immunol Immunother; 1989; 29(2):93-100. PubMed ID: 2720709
[TBL] [Abstract][Full Text] [Related]
56. Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes.
Uchida A; Micksche M; Hoshino T
Cancer Immunol Immunother; 1984; 18(1):5-12. PubMed ID: 6333269
[TBL] [Abstract][Full Text] [Related]
57. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
Parkhurst MR; Riley JP; Dudley ME; Rosenberg SA
Clin Cancer Res; 2011 Oct; 17(19):6287-97. PubMed ID: 21844012
[TBL] [Abstract][Full Text] [Related]
58. Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF).
Kedar E; Ikejiri BL; Gorelik E; Herbermann RB
Cancer Immunol Immunother; 1982; 13(1):14-23. PubMed ID: 6984352
[TBL] [Abstract][Full Text] [Related]
59. Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients.
Inoue Y; Shijubo N; Uede T
Jpn J Cancer Res; 1990 Oct; 81(10):1012-20. PubMed ID: 2172193
[TBL] [Abstract][Full Text] [Related]
60. Oxidized-Desialylated Low-Density Lipoprotein Inhibits the Antitumor Functions of Lymphokine Activated Killer Cells.
Aguilar Díaz de León JS; Glenn HL; Knappenberger M; Borges CR
J Cancer; 2021; 12(16):4993-5004. PubMed ID: 34234868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
